تصفح College of Pharmacy حسب المؤلف "Kaddoura, Rasha"
-
Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): A systematic review and meta-analysis
Kaddoura, Rasha; Madurasinghe, Vichithranie; Chapra, Ammar; Abushanab, Dina; Al-Badriyeh, Daoud; Patel, Ashfaq... more authors ... less authors ( Elsevier Inc. , 2024 , Article)Introduction: While beta-blockers are considered the cornerstone of treatment for heart failure with reduced ejection fraction, the same may not apply to patients with heart failure with preserved ejection fraction (HFpEF). ... -
Clinical pharmacists’ interventions for preventing adverse events in critically ill neonates in Qatar: an economic impact analysis
Yakti, Ola; Al-Badriyeh, Daoud; Rijims, Mohammed; Abdelaal, Mohammed; Alsoukhni, Omar; Al Hail, Moza; Abdulrouf, Palli Valapila; El-Kassem, Wessam; Abounahia, Fouad; Kaddoura, Rasha; Abushanab, Dina... more authors ... less authors ( Springer Nature , 2024 , Article)Objective: This study aimed to assess the overall economic impact of clinical pharmacist interventions in the neonatal ICU (NICU) in Qatar. Methods: A retrospective review of neonates’ records was performed over a 3-month ... -
Cost-Effectiveness Analysis of Sacubitril/Valsartan for Reducing the Use of Implantable Cardioverter-Defibrillator (ICD) and the Risk of Death in ICD-Eligible Heart Failure Patients with Reduced Ejection Fraction
Kaddoura, Rasha; Abushanab, Dina; Arabi, Abdul Rahman; Alyafei, Sumaya Alsaadi; Al-Badriyeh, Daoud ( Elsevier , 2022 , Article)Although previous cost‐effectiveness evaluations of sacubitril/valsartan have demonstrated cardiovascular and economic benefits in heart failure patients with reduced ejection fraction (HFrEF), whether sacubitril/valsartan ... -
Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes
Abushanab, Dina; Chbib, Salma; Kaddoura, Rasha; Al Hail, Moza; Abdul Rouf, Palli Valappila; El Kassem, Wessam; Shah, Jassim; Ravindran Nair, Ramesh Kumar; Al-Badriyeh, Daoud... more authors ... less authors ( Taylor & Francis , 2024 , Article)Aim: To evaluate the cost-effectiveness of dapagliflozin added to standard of care (SoC) versus SoC in heart failure with reduced ejection fraction (HFrEF) and without type 2 diabetes mellitus (T2DM) patients from the ... -
Effectiveness of a structured pharmacist-delivered intervention for patients post-acute coronary syndromes on all-cause hospitalizations and cardiac-related hospital readmissions: a prospective quasi-experimental study
El Hajj, Maguy Saffouh; Kaddoura, Rasha; Abu Yousef, Safae E.A.; Orabi, Bassant; Awaisu, Ahmed; AlYafei, Sumaya; Shami, Rula; Mahfoud, Ziyad R.... more authors ... less authors ( Springer , 2023 , Article)Background: Acute coronary syndrome (ACS) is a leading cause of mortality and morbidity in Qatar and globally. Aim: The primary objective of the study was to evaluate the effectiveness of a structured clinical pharmacist-delivered ... -
Has low-dose intracoronary thrombolysis gained ground in primary percutaneous intervention?
Kaddoura, Rasha; Mohamed Ibrahim, Mohamed Izham; Arabi, Abdul Rahman ( SAGE , 2022 , Article)Reducing thrombus burden would improve patient’s outcomes. Low-dose intracoronary thrombolytic agent administration has been considered to improve myocardial microcirculation, cardiac function, and major adverse cardiovascular ... -
Intracoronary pharmacological therapy versus aspiration thrombectomy in STEMI (IPAT-STEMI): A systematic review and meta-analysis of randomized trials
Kaddoura, Rasha; Mohamed Ibrahim, Mohamed Izham; Al-Badriyeh, Daoud; Omar, Amr; Al-Kindi, Fahad; Arabi, Abdul Rahman... more authors ... less authors ( Public Library of Science , 2022 , Article)Background Thrombus load in STEMI patients remains a challenge in practice. It aggravates coronary obstruction leading to impaired myocardial perfusion, worsened cardiac function, and adverse clinical outcomes. Various ...